Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.

Expert opinion on drug metabolism & toxicology - 1 Jan 2015

Yang Yao, Lewis Joshua P, Hulot Jean-Sébastien, Scott Stuart A

Abstract excerpt

INTRODUCTION: Aspirin, clopidogrel, prasugrel and ticagrelor are antiplatelet agents for the prevention of ischemic events in patients with acute coronary syndromes (ACS), percutaneous coronary intervention (PCI) and other indications. Variability in response is observed to different degrees with these agents, which can translate to increased risks for adverse cardiovascular events. As such, potential...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiovascular Diseases
Share to Clopidogrel
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Pharmacogenetics

Share to Platelet Aggregation Inhibitors

Share to Ticlopidine

Source

Open in PubMed Open full text

Identifiers

PMID: 26173871
DOI: 10.1517/17425255.2015.1068757
PMCID: PMC4829114

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.PMID 26173871Read ↗

Genetic and nongenetic factors influencing the response to clopidogrel.Semantic proximity Read ↗

The pharmacogenetics of antiplatelet agents: towards personalized therapy?Semantic proximity Read ↗

Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.Semantic proximity Read ↗

Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular MedicineSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.Semantic proximity Read ↗

Pharmacogenetics of P2Y 12 receptor inhibitorsSemantic proximity Read ↗

Genotyping genetic variants of CYP2C19 for precision antiplatelet dosing: state of the art and future perspectives.Semantic proximity Read ↗

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.Semantic proximity Read ↗

Recent advances in the pharmacogenetics of clopidogrel.Semantic proximity Read ↗

Pharmacogenetics of clopidogrel.Semantic proximity Read ↗

Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium.Semantic proximity Read ↗

Clopidogrel pharmacogenetics: Beyond candidate genes and genome-wide association studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.